drugset / Trial / NCT02318394
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of MEDI0562 in adult subjects with selected advanced solid tumors
Timeline
- Start
- 2015-03-02
- Primary completion
- 2018-01-09
- Completion
- 2018-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAVOLIMAB | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 10 mg/kg | Intravenous |